GSK bets $10.6bn on lung cancer with third major deal of 2026

GSK has agreed to acquire the US oncology specialist Nuvalent for $10.6 billion, a bold bet on the future of lung-cancer treatment and the British drugmaker's third major acquisition in the first half of 2026 alone. The deal underlines chief executive ambitions to rebuild GSK around oncology and respiratory medicine as the company prepares for the loss of patent protection on some of its biggest earners.

Under the agreement, GSK will launch a tender offer for all of Nuvalent's outstanding shares at $124 each in cash. The price represents a substantial premium, and Nuvalent's shares surged by close to 40% when the talks were confirmed, reflecting investor enthusiasm for the biotech's late-stage pipeline.

This is general business news rather than investment advice, but the transaction offers a window into the high-stakes arithmetic facing big pharma, where the only reliable way to replace expiring blockbusters is to buy the science before it reaches the market.

What GSK is buying

The strategic heart of the deal is a pair of late-stage cancer drugs: zidesamtinib and neladalkib. Both are precision medicines designed to target specific genetic alterations, ROS1 and ALK respectively, that drive certain forms of non-small-cell lung cancer, the most common type of the disease. Both are currently under review by the US Food and Drug Administration, with decisions expected in September and November.

Beyond those two flagship assets, GSK also gains a broader lung-cancer platform, including an earlier-stage HER2 inhibitor known as NVL-330. If the lead drugs win approval and live up to their clinical promise, they could give GSK a strong foothold in a lucrative and fast-growing corner of cancer treatment.

“Big pharma cannot research its way out of a patent cliff fast enough, so it buys late-stage biotech instead. The premium looks steep until you remember what a successful precision oncology franchise is worth.”

— An analyst covering the pharmaceutical sector

The patent cliff driving the deal

The urgency behind GSK's dealmaking comes down to a looming threat familiar to every large drug company: the patent cliff. The acquisition is widely seen as a way to help offset the revenue GSK expects to lose when its best-selling HIV medicine loses exclusivity from 2028, opening the door to cheaper generic competition.

Faced with that prospect, GSK has gone shopping aggressively, with the Nuvalent purchase marking its third significant acquisition of the year. The strategy carries risk: late-stage drugs can still fail in front of regulators, and paying a hefty premium for assets that have not yet reached the market is a gamble. But for a company staring at a revenue hole later this decade, standing still is arguably the bigger risk.

• GSK will pay $124 per share in cash, valuing Nuvalent at around $10.6 billion.
• Nuvalent shares jumped roughly 39% when the deal was confirmed.
• The two lead drugs, zidesamtinib and neladalkib, target ROS1- and ALK-altered non-small-cell lung cancer.
• Both are under FDA review, with decisions expected in September and November.
• GSK also gains an earlier-stage HER2 inhibitor, NVL-330.
• The acquisition is GSK's third major deal of 2026 and is expected to close in the third quarter.

Background

GSK, one of the largest companies on the London Stock Exchange, has spent recent years reshaping itself around vaccines, specialty medicines and oncology after spinning off its consumer-health business. Cancer treatment has become a central plank of that strategy, and the company has made repeated acquisitions to bolster a pipeline that was once seen as thinner than those of its biggest rivals.

Precision oncology, in which drugs are matched to the specific genetic mutations driving a patient's tumour, has transformed parts of cancer care over the past decade and become one of the most fiercely contested areas of pharmaceutical research. Nuvalent's focus on hard-to-treat genetic subtypes of lung cancer places it squarely in that competitive arena.

What happens next

The transaction is subject to antitrust clearance and customary closing conditions and is expected to complete in the third quarter of 2026. The bigger tests will come later: the FDA verdicts on the two lead drugs this autumn will determine whether GSK has bought a future blockbuster franchise or paid top dollar for promise that has yet to be proven. For a company racing the clock on its patent cliff, the next few months could hardly matter more.